[Form 4] ResMed Inc. Insider Trading Activity

Rhea-AI Filing Summary

Insider acquisition of ResMed common stock via vested performance awards. Michael J. Rider, Global General Counsel and Secretary of ResMed Inc. (RMD), reported that 2,941 shares of ResMed common stock were acquired on 08/15/2025 at a $0 price as the result of performance-based restricted stock units granted on 11/20/2024 that vested when the compensation committee certified performance metrics were met. After the transaction, Rider beneficially owns 11,427 shares. The filing indicates the award vests in one-third increments annually on the grant anniversary; no cash purchase occurred. This Form 4 was signed on 08/19/2025.

Positive

• 2,941 shares acquired through earned performance-based restricted stock units, reflecting achievement of pre-established performance metrics
• Total beneficial ownership increased to 11,427 shares for the reporting person, disclosed under Section 16

Negative

• None.

Insights

Financial Analyst

TL;DR: Insider received vested performance RSUs totaling 2,941 shares, increasing ownership to 11,427 shares; this is a routine compensation event.

The transaction reflects the vesting of performance-based restricted stock units previously granted, recorded as an acquisition at $0 per share because these are compensation-settled awards rather than market purchases. The reporting person is a senior executive (Global General Counsel and Secretary), and the filing clarifies the award schedule (1/3 vesting each grant anniversary). From an analytical perspective, this is a compensation realization rather than a market-directed buy or sell and carries limited direct valuation impact on outstanding share counts.

Corporate Governance Expert

TL;DR: Vesting certification by the compensation committee triggered issuance of earned RSUs; disclosure follows Section 16 reporting rules.

The Form 4 documents compliance with insider reporting obligations following certification that performance metrics were met. The explanation states the original grant date and vesting cadence, providing transparency on executive pay realization. There is no indication of any related-party transaction, amendment, or sale; the filing appears routine and consistent with typical equity compensation governance processes.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rider Michael J

(Last) (First) (Middle)

9001 SPECTRUM CENTER BLVD

(Street)

SAN DIEGO CA 92123

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Global General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
08/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
ResMed Common Stock	08/15/2025		A(1)		2,941	A	$0	11,427	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents performance-based restricted stock units granted on November 20, 2024. The shares were earned on August 15, 2025, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant.

	Michael J. Rider, Global General Counsel and Secretary	08/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Michael J. Rider report on the Form 4 for RMD?

He reported acquisition of 2,941 ResMed shares on 08/15/2025 due to vesting of performance-based RSUs; beneficial ownership after the transaction is 11,427 shares.

Why was the price reported as $0 on the Form 4?

The shares resulted from vested compensation (performance-based RSUs), which are reported as acquired at $0 because no cash purchase occurred.

When were the performance-based RSUs originally granted?

The RSUs were granted on November 20, 2024, and the shares were earned when the compensation committee certified performance metrics on 08/15/2025.

What is the vesting schedule for these RSUs?

Stock units vest one-third each year on the anniversary of the grant, per the filing's explanation of responses.

When was the Form 4 signed and filed?

The signature date on the Form 4 is 08/19/2025, signed by Michael J. Rider, Global General Counsel and Secretary.